--- title: Buy Brilinta (Ticagrelor) 60mg, 90mg Pills Online description: Brilinta (Ticagrelor) 60mg and 90mg pills is a trusted treatment to prevent heart attacks and strokes. Order from our secure pharmacy for verified quality. type: product language: en url: https://medsforsale.net/buy-brilinta-online-en availability: in_stock price_min: 27.99 price_max: 306.99 currency: USD offers: - name: 60mg x 14 pills price: 27.99 - name: 60mg x 28 pills price: 49.99 - name: 60mg x 56 pills price: 86.99 - name: 60mg x 84 pills price: 118.99 - name: 60mg x 112 pills price: 133.99 - name: 60mg x 168 pills price: 167.99 - name: 90mg x 14 pills price: 63.99 - name: 90mg x 28 pills price: 81.99 - name: 90mg x 56 pills price: 140.99 - name: 90mg x 84 pills price: 191.99 - name: 90mg x 112 pills price: 230.99 - name: 90mg x 168 pills price: 306.99 --- # Buy Brilinta (Ticagrelor) 60mg, 90mg Pills Online Brilinta, featuring the active ingredient Ticagrelor, is an antiplatelet medication originally developed by AstraZeneca. It is designed to prevent blood clots and reduce the risk of cardiovascular events like heart attacks or strokes in patients with a history of heart conditions. This medication is essential for adults prioritizing long-term heart health and recovery. Our pharmacy provides a professional and reliable source for Brilinta, available in both 60mg and 90mg pills to suit your prescribed treatment plan. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **60mg** | 14 pills | **$27.99** | $2.00 | In Stock | | **60mg** | 28 pills | **$49.99** | $1.79 | In Stock | | **60mg** | 56 pills | **$86.99** | $1.55 | In Stock | | **60mg** | 84 pills | **$118.99** | $1.42 | In Stock | | **60mg** | 112 pills | **$133.99** | $1.20 | In Stock | | **60mg** | 168 pills | **$167.99** | $1.00 | In Stock | | **90mg** | 14 pills | **$63.99** | $4.57 | In Stock | | **90mg** | 28 pills | **$81.99** | $2.93 | In Stock | | **90mg** | 56 pills | **$140.99** | $2.52 | In Stock | | **90mg** | 84 pills | **$191.99** | $2.29 | In Stock | | **90mg** | 112 pills | **$230.99** | $2.06 | In Stock | | **90mg** | 168 pills | **$306.99** | $1.83 | In Stock | [Buy Now](https://medsforsale.net/buy-brilinta-online-en) ## Introduction Brilinta (ticagrelor) is an oral antiplatelet agent indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in adults with acute coronary syndrome (ACS) and in patients with a history of myocardial infarction undergoing long-term secondary prevention. The medication is supplied as film-coated tablets in 60 mg and 90 mg strengths. Brilinta belongs to the class of P2Y₁₂ receptor antagonists, a group of drugs that inhibit platelet aggregation by blocking the ADP-dependent pathway. In addition to its approved uses, ticagrelor is explored in several off-label contexts, though such applications have not received formal regulatory endorsement. ## What is Brilinta? Brilinta is the trade name for ticagrelor, a reversible antagonist of the platelet P2Y₁₂ receptor. Developed by AstraZeneca, Brilinta received FDA approval in 2011 for the treatment of ACS and later received EMA approval for the same indication and for secondary prevention after myocardial infarction. The drug is marketed under brand names such as Brilinta (United States) and Brilique (European Union and elsewhere). It is supplied as film-coated tablets containing either 60 mg or 90 mg of ticagrelor. ## How Brilinta Works Ticagrelor binds to the P2Y₁₂ ADP receptor on platelet surfaces without requiring metabolic activation. By occupying the receptor, it blocks ADP-mediated signaling that normally leads to conformational changes in the GPIIb/IIIa complex, a critical step for platelet aggregation and thrombus formation. Unlike the thienopyridine class (e.g., clopidogrel), ticagrelor’s inhibition is reversible and does not depend on hepatic CYP2C19 conversion. After oral administration, peak plasma concentrations occur within 1-3 hours; the drug’s half-life is approximately 7 hours, and platelet inhibition persists for about 24 hours with twice-daily dosing. ## Conditions Treated with Brilinta - **Acute Coronary Syndrome (ACS)** - includes unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). Brilinta, when combined with low-dose aspirin, significantly lowers the composite endpoint of cardiovascular death, myocardial infarction, or stroke compared with clopidogrel (PLATO trial). - **Secondary Prevention after Myocardial Infarction** - for patients who have survived a myocardial infarction, long-term therapy (up to 12 months) with ticagrelor plus aspirin reduces recurrent ischemic events relative to aspirin alone. The drug’s efficacy in these settings derives from its rapid, potent, and consistent inhibition of platelet activation, which is crucial during the heightened thrombotic risk period following coronary plaque rupture. ## Off-Label and Investigational Uses of Brilinta - **Peripheral Arterial Disease (PAD)** - Small randomized studies suggest ticagrelor may improve walking distance and reduce limb ischemic events when added to standard antiplatelet therapy, although larger trials are pending. - **Stroke Prevention in Non-Cardioembolic Ischemic Stroke** - Observational data indicate possible benefit in preventing recurrent stroke, but the evidence remains insufficient for formal endorsement. - **COVID-19-related Coagulopathy** - Early phase investigations examined ticagrelor’s anti-inflammatory and antithrombotic properties in severe COVID-19, yet definitive conclusions are lacking. These applications have not been approved by the FDA, EMA, or other national agencies. Patients should discuss any off-label consideration with a qualified healthcare professional, and such use should occur only under direct medical supervision. ## Is Brilinta the Right Medication for You? Brilinta is appropriate for adult patients who have experienced an ACS event or who are undergoing secondary prevention after myocardial infarction, provided there are no contraindications. It is particularly advantageous when rapid and consistent platelet inhibition is required, such as in early invasive management of STEMI. Patients with a history of hemorrhagic stroke, active pathological bleeding, or severe hepatic impairment are generally excluded. Additionally, individuals taking strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may experience increased ticagrelor exposure and should avoid concomitant use. ## Risks, Side Effects, and Interactions ### Common - Dyspnea (shortness of breath) - reported in up to 14 % of users; often mild and transient. - Headache. - Nausea, dyspepsia, or abdominal discomfort. - Increased serum uric acid levels (gout flares in predisposed patients). ### Rare - Bradycardia or clinically significant atrioventricular block. - Pruritus or rash. - Elevated liver enzymes (ALT/AST). ### Serious - Major bleeding, including intracranial hemorrhage. - Severe allergic reactions (anaphylaxis, angioedema). - Life-threatening dyspnea leading to discontinuation. ### Drug-Drug Interactions - **Strong CYP3A4 inhibitors** (ketoconazole, clarithromycin, ritonavir) increase ticagrelor plasma concentrations; co-administration is contraindicated. - **Strong CYP3A4 inducers** (rifampin, carbamazepine, phenytoin) reduce effectiveness; avoid or adjust therapy. - **Concomitant anticoagulants** (warfarin, DOACs) heighten bleeding risk; close monitoring is required. - **Non-steroidal anti-inflammatory drugs (NSAIDs)** augment gastrointestinal bleeding potential. ### Drug-Food Interactions - High-fat meals modestly delay ticagrelor absorption but do not affect overall exposure; the drug may be taken with or without food. - Grapefruit juice can inhibit CYP3A4 and should be avoided. Patients should report any unexpected bleeding, severe shortness of breath, or allergic symptoms promptly. ## Use: Dosing, Missed Dose, Overdose **Standard dosing for ACS** - 180 mg loading dose (three 60 mg tablets taken together) followed by 90 mg twice daily for at least 12 months, together with low-dose aspirin (75-100 mg daily). **Secondary prevention** - 60 mg twice daily in combination with aspirin, initiated at least one month after the acute event and continued for up to 12 months. **Missed dose** - If a dose is missed and the scheduled time is less than 12 hours away, take the missed tablet immediately; otherwise, skip it and resume the regular twice-daily schedule. Do not double the dose to compensate. **Overdose** - Symptoms may include excessive bleeding, severe dyspnea, or syncope. Seek emergency medical care. Supportive measures include monitoring for bleeding, platelet transfusion if indicated, and symptomatic treatment. No specific antidote exists. **Practical precautions** - Brilinta should be swallowed whole with water; crushing may alter release characteristics. Avoid alcohol excess, as it can exacerbate bleeding risk. Patients should refrain from operating heavy machinery or driving if they experience dyspnea or dizziness. ## FAQ - **What should I know about storing Brilinta tablets?** Brilinta should be kept at controlled room temperature (20-25 °C) away from moisture and direct sunlight. Do not store in the bathroom or near a stove. - **Can I travel internationally with Brilinta?** Yes, but keep the medication in its original packaging with a copy of the prescription (or a physician’s letter) to satisfy customs regulations. Pack the tablets in a carry-on bag to avoid temperature extremes. - **Does ticagrelor have any effect on blood glucose levels?** Current evidence indicates ticagrelor does not significantly alter glycemic control. Diabetic patients should continue routine glucose monitoring as advised by their care team. - **Why does Brilinta cause shortness of breath in some patients?** The dyspnea is thought to arise from ticagrelor’s action on adenosine metabolism, leading to increased extracellular adenosine that stimulates pulmonary receptors. The symptom is usually mild and resolves with continued therapy or dose adjustment. - **Are there any differences between the 60 mg and 90 mg tablets besides strength?** Both strengths share the same excipients and film coating; the only difference is the amount of active ticagrelor per tablet. Dosing decisions are based on clinical indication and patient tolerance. - **What inactive ingredients are present in Brilinta tablets?** Common inactive components include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. Patients with severe lactose intolerance should discuss alternatives with their clinician. - **Is ticagrelor detectable in standard drug-testing panels?** Ticagrelor is not screened for in typical occupational or sports drug tests because it is not a prohibited substance. However, specialized testing can detect its presence if specifically requested. - **How does Brilinta compare with clopidogrel in terms of platelet inhibition?** Ticagrelor provides faster, more consistent, and reversible inhibition of the P2Y₁₂ receptor, achieving >90 % platelet inhibition within 2 hours, whereas clopidogrel’s effect is slower and variable due to genetic differences in CYP2C19 metabolism. - **Can Brilinta be used in patients with chronic kidney disease (CKD)?** Ticagrelor is partially eliminated via the kidneys, but no dose adjustment is needed for mild to moderate CKD (eGFR ≥ 30 mL/min). In severe renal impairment (eGFR < 30 mL/min), clinical judgment is required, and the drug is generally avoided due to limited data. - **What is the rationale for combining Brilinta with low-dose aspirin?** Dual antiplatelet therapy (DAPT) synergistically blocks both the ADP-mediated and thromboxane-A₂ pathways, offering superior protection against arterial thrombus formation compared with aspirin alone. ## Glossary **P2Y₁₂ receptor** : A platelet surface receptor activated by ADP, essential for platelet aggregation. Blocking this receptor reduces clot formation. **Dual antiplatelet therapy (DAPT)** : The combined use of two antiplatelet agents, typically a P2Y₁₂ inhibitor (e.g., ticagrelor) and aspirin, to provide enhanced protection against arterial thrombosis. **Reversible inhibition** : A pharmacologic effect that can be undone as the drug dissociates from its target, allowing platelet function to recover sooner after discontinuation. **CYP3A4** : An enzyme in the liver that metabolizes many drugs, including ticagrelor; inhibitors or inducers of this enzyme can markedly alter ticagrelor levels. ## Buying Brilinta from [our online pharmacy](https://medsforsale.net/buy-brilinta-online-en) Patients seeking reliable access to Brilinta can obtain the medication through **[our online pharmacy](https://medsforsale.net/buy-brilinta-online-en)**. We source all tablets from licensed, audited suppliers that meet international quality standards, ensuring each batch matches the specifications required by regulatory authorities. Because we operate as a pharmacy-broker service, we can provide Brilinta at prices close to the manufacturer’s cost, which helps reduce the financial burden for individuals without adequate insurance coverage. Our fulfillment process prioritizes discretion and timeliness. Packages are sealed in plain, unbranded envelopes and shipped via secure carriers, with typical delivery windows of 7 days for express service or approximately 3 weeks for standard airmail. The service is designed for patients who encounter limited availability through local pharmacies or who prefer a private, cost-effective channel for obtaining their medication. By choosing **[our online pharmacy](https://medsforsale.net/buy-brilinta-online-en)**, you benefit from a vetted supply chain, transparent pricing, and a commitment to privacy throughout the ordering and delivery experience. ## Disclaimer The information presented about **Brilinta** is intended for general educational purposes and does not replace individualized medical advice. Treatment choices, including any off-label applications, should be made in consultation with a qualified healthcare professional. Readers are presumed to be competent adults capable of assessing health information responsibly. **[our online pharmacy](https://medsforsale.net/buy-brilinta-online-en)** supplies Brilinta to individuals who may encounter obstacles accessing the medication through conventional pharmacy channels or who are looking for affordable generic alternatives. Always discuss initiation, modification, or cessation of any medication with a qualified health-care provider.